Stay updated on Resmetirom in NASH and Fibrosis Clinical Trial
Sign up to get notified when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.

Latest updates to the Resmetirom in NASH and Fibrosis Clinical Trial page
- CheckyesterdayChange DetectedThe page now lists an additional MeSH term 'Non-alcoholic fatty liver disease' and a related topic 'MedlinePlus Genetics', and shows the revision tag v3.3.4.SummaryDifference0.1%

- Check8 days agoChange DetectedRemoved specific related topics from the page: Non-alcoholic fatty liver disease and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check30 days agoChange DetectedExpanded recruitment locations to include numerous sites across the United States and internationally, and added related topics such as Non-alcoholic fatty liver disease and MedlinePlus Genetics. The HHS Vulnerability Disclosure item was removed.SummaryDifference2%

- Check37 days agoChange DetectedDeleted related topics: Non-alcoholic fatty liver disease and MedlinePlus Genetics from the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check44 days agoChange Detected- Added related topics: Non-alcoholic fatty liver disease and MedlinePlus Genetics.SummaryDifference0.0%

- Check52 days agoChange DetectedAdded Revision: v3.3.2 under additions. Removed 'Non-alcoholic fatty liver disease', 'MedlinePlus Genetics' related topic, and Revision: v3.3.1 from deletions.SummaryDifference0.1%

Stay in the know with updates to Resmetirom in NASH and Fibrosis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom in NASH and Fibrosis Clinical Trial page.